Iv Liver Disease
First patient treated in Takeda’s phase 3 trial for alpha-1 antitrypsin deficiency
Arrowhead Pharmaceuticals announced that the first patient has been treated in Takeda Pharmaceuticals’ phase 3 clinical trial of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver disease.
The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality
The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.
Hepatitis B Foundation names Baruch S. Blumberg Prize winner
The Hepatitis B Foundation has awarded Stephen Urban, PhD, the 2023 Baruch S. Blumberg Prize for his development of bulevirtide, the first drug approved for the treatment of hepatitis D.
‘We have to do better’: Liver health equity demands research investment to match burden
WASHINGTON — Funding research into liver disease, and reducing inequities in liver care, requires investment proportionate to its prevalence and burden on the health care system, said a keynote speaker at The Liver Meeting.
Alcohol use disorders may drive HCC progression in patients with diabetes
LONDON — Alcohol misuse was a primary trigger for progression of liver disease to hepatocellular carcinoma among a subset of French patients with type 2 diabetes, according to data presented at the International Liver Congress.
Heavy alcohol use increases liver impairment, risk for HCC in hepatitis-induced cirrhosis
Among patients with hepatitis-induced cirrhosis, heavy alcohol consumption increased liver function impairment and hepatocellular carcinoma prevalence, according to research.